Structure of Ozanimod
CAS No.: 1306760-87-1
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Ozanimod is an oral, once daily, selective sphingosine 1-phosphate 1 and 5 receptor modulator in development for autoimmune indications including relapsing multiple sclerosis (RMS) and ulcerative colitis (UC).
Synonyms: RPC-1063
4.5
*For Research Use Only !
Change View
| Size | Price | VIP Price |
DE Stock US Stock |
Asia Stock Global Stock |
In Stock |
| {[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock Inquiry - | Login - + |
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Targeting SleC and CspB in the Inhibition of Spore Germination in Clostridioides difficile
Yang, Jingdong ; Qian, Yuanyuan ; Kim, Choon ; Birhanu, Biruk T ; Cal y Mayor-Luna, Carlos ; Ding, Derong , et al.
Abstract: Clostridioides difficile, a Gram-positive, spore-forming anaerobic bacterium, is a major healthcare threat. Its spores colonize the gut following dysbiosis caused by broad-spectrum antibiotics, remaining dormant until host’s bile acid triggers germination into vegetative cells that produce toxins, leading to diarrhea, colitis, and potentially death. Current antibiotics to treat C. difficile infection target vegetative cells but not spore germination, a pivotal step in infection development. This study unveils 1,2,4-oxadiazoles as a novel class of spore germination inhibitors and delineates the structure−activity relationship. Screening of 120 oxadiazoles revealed compound 110 (IC50 = 14 ± 1 μM or 6.3 ± 0.4 μg/mL). Compound 110 targets mature SleC (Kd = 12 ± 1.0 μM) and CspB (Kd = 8.0 ± 1.0 μM) on spores, inhibiting their enzymatic activities, thus preventing spore germination. To our knowledge, compound 110 is the first reported spore germination inhibitor targeting SleC/CspB, offering a promising avenue for C. difficile therapies.
Show More >
| CAS No. : | 1306760-87-1 |
| Formula : | C23H24N4O3 |
| M.W : | 404.46 |
| SMILES Code : | N#CC1=CC(C2=NC(C3=CC=CC4=C3CC[C@@H]4NCCO)=NO2)=CC=C1OC(C)C |
| Synonyms : |
RPC-1063
|
| MDL No. : | MFCD28386168 |
| InChI Key : | XRVDGNKRPOAQTN-FQEVSTJZSA-N |
| Pubchem ID : | 52938427 |
| GHS Pictogram: |
|
| Signal Word: | Warning |
| Hazard Statements: | H302 |
| Precautionary Statements: | P280-P305+P351+P338 |
In Vitro:
|
Cell Line
|
Concentration | Treated Time | Description | References |
| HEK293T cells | 1 μM | 1 hour | To assess the ability of Ozanimod to induce S1P1 receptor internalization, results showed that Ozanimod significantly reduced cell surface expression of S1P1 receptors. | Br J Pharmacol. 2016 Jun;173(11):1778-92. |
| BV2 cells | 1000 nM | 2 hours | Ozanimod treatment downregulated IL-6, RANTES/CCL5, and TNF mRNAs | Cells. 2020 May 22;9(5):1290. |
In Vivo:
|
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
| C57BL/6 mice | Experimental autoimmune encephalitis (EAE) model | Oral | 0.2 and 0.6 mg/kg | Once daily for 14 days | To evaluate the therapeutic effects of Ozanimod in the EAE model, results showed that Ozanimod dose-dependently reduced disease scores and weight loss. | Br J Pharmacol. 2016 Jun;173(11):1778-92. |
| C57BL/6 female mice | Experimental autoimmune encephalomyelitis (EAE) | Oral | 0.6mg/kg | Daily administration for 21 days | Ozanimod treatment significantly improved clinical symptoms in EAE mice, reduced the percentage of autoreactive CD4+ and CD8+ T cells, and significantly inhibited lymphocyte infiltration into the spinal cord, accompanied by reversed demyelination. Furthermore, ozanimod treatment resulted in a significant increase in the frequency of total NK cells in the blood and CNS along with upregulation of the activating receptor NKG2D on CD27low/- NK cell subset in the CNS. The effectiveness of ozanimod treatment in inhibiting the progression of the disease was reduced when NK cells were depleted using anti-NK1.1 mAb. | Front Immunol. 2024 Mar 12;15:1230735 |
| Mice | Cerebrovascular thrombosis model | Intravenous injection | 0.6 mg/kg | Single dose, observed for 90 minutes | To evaluate the effects of Ozanimod combined with low-dose tPA on microvascular hemodynamics following cerebrovascular thrombosis. Results showed that Ozanimod significantly restored flow velocity after thrombosis, reduced thrombus volume, and did not affect coagulation and bleeding time. | Front Immunol. 2022 May 27;13:801727 |
Clinical Trial:
| NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
| NCT04211558 | Healthy Volunteer | PHASE1 | COMPLETED | 2020-10-09 | Capital Medical University - B... More >>eijing Anzhen Hospital, Beijing, 100029, China Less << |
| NCT05076175 | Colitis, Ulcerative | PHASE2|PHASE3 | RECRUITING | 2031-08-14 | Local Institution - 0041, Phoe... More >>nix, Arizona, 85016-7710, United States|University of Arizona, Tucson, Arizona, 85724, United States|Local Institution - 0052, Garden Grove, California, 92845, United States|Loma Linda University Health System, Loma Linda, California, 92354, United States|Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States|Lucile Packard Children's Hospital, Palo Alto, California, 94304, United States|Local Institution - 0096, Sacramento, California, 95817, United States|Local Institution - 0007, Hartford, Connecticut, 06106, United States|Children's National Medical Center, Washington, District of Columbia, 20010, United States|Local Institution - 0075, Orlando, Florida, 32803, United States|Local Institution - 0016, Atlanta, Georgia, 30342, United States|University of Iowa, Iowa City, Iowa, 52242, United States|Maine Medical Partners, Portland, Maine, 04102, United States|Boston Children's Hospital, Boston, Massachusetts, 02115, United States|Local Institution - 0042, Springfield, Massachusetts, 01199, United States|University of Massachusetts Chan Medical School, Worcester, Massachusetts, 01655, United States|Children's Hospital of Michigan, Detroit, Michigan, 48201, United States|Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota, 55905, United States|Washington University, Saint Louis, Missouri, 63110, United States|Local Institution - 0028, New York, New York, 10029, United States|Columbia University Medical Center, New York, New York, 10032, United States|Local Institution - 0023, New York, New York, 10065, United States|University of North Carolina Medical Center, Chapel Hill, North Carolina, 27599, United States|Local Institution - 0047, Charlotte, North Carolina, 28203, United States|Cleveland Clinic, Cleveland, Ohio, 44124, United States|Local Institution - 0062, Oklahoma City, Oklahoma, 73112, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, 17033, United States|Texas Children's Hospital, Houston, Texas, 77030, United States|Seattle Children's Hospital, Seattle, Washington, 98105, United States|Swedish Medical Center, Seattle, Washington, 98122, United States|MultiCare Health System, Tacoma, Washington, 98405, United States|Children's Wisconsin, Milwaukee, Wisconsin, 53226, United States|Local Institution - 0094, Westmead, New South Wales, 2145, Australia|Monash Health, Clayton, Victoria, 3168, Australia|Local Institution - 0086, Murdoch, Western Australia, 6150, Australia|Local Institution - 0076, Brussels, Bruxelles-Capitale, Région De, 1090, Belgium|Local Institution - 0059, Leuven, Vlaams-Brabant, 3000, Belgium|Local Institution - 0056, Brussels, 1090, Belgium|Local Institution - 0063, Edegem, 2650, Belgium|Local Institution - 0061, Liège, 4000, Belgium|Local Institution - 0071, Liège, 4000, Belgium|Local Institution - 0083, Hamilton, Ontario, L8N 3Z5, Canada|Local Institution - 0082, Toronto, Ontario, M5G 1X8, Canada|CHU de Toulouse - H?pital des Enfants, Toulouse, Haute-Garonne, 31059, France|Hospices Civils de Lyon - H?pital Femme Mère Enfant, Bron, 69500, France|Centre Hospitalier Universitaire de Caen - H?pital C?te de Nacre, Caen, 14033, France|H?pital Universitaire Necker Enfants Malades, Paris, 75015, France|Local Institution - 0073, Paris, 75571, France|Klinikum der Ludwig-Maximilians-Universitaet Muenchen, München, Bayern, 80337, Germany|Local Institution - 0097, Leipzig, Sachsen, 04103, Germany|Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, 01307, Germany|Schneider Children's Medical Center, Petah-Tikva, HaMerkaz, 49202, Israel|Rambam Health Care Campus, Haifa, HaTsafon, 3109601, Israel|Local Institution - 0019, Jerusalem, Yerushalayim, 9013102, Israel|Local Institution - 0025, Obu, Aichi, 474-8710, Japan|Local Institution - 0011, Kurume-shi, Fukuoka, 8300011, Japan|Local Institution - 0068, Komatsu, Ishikawa, 923-8560, Japan|Local Institution - 0038, Yokohama-shi, Kanagawa, 2300012, Japan|Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Osaka, 569-8686, Japan|Tokyo Medical and Dental University Hospital, Bunkyo-ku, Tokyo, 1138519, Japan|National Center for Child Health and Development, Setagaya-ku, Tokyo, 1578535, Japan|Local Institution - 0033, Shinjuku-ku, Tokyo, 160-0023, Japan|Hiroshima University Hospital, Hiroshima, 7348551, Japan|Local Institution - 0010, Tokyo, 113-8431, Japan|Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroc?awiu, Wroc?aw, Dolno?l?skie, 50-369, Poland|Local Institution - 0043, Warsaw, Mazowieckie, 00-728, Poland|Centrum Zdrowia Dziecka w Warszawie, Warsaw, Mazowieckie, 04-746, Poland|Local Institution - 0084, Krakow, Ma?opolskie, 30-663, Poland|Local Institution - 0015, Rzeszów, Podkarpackie, 35-302, Poland|Local Institution - 0013, Gdansk, Pomorskie, 80-803, Poland|Local Institution - 0079, Gdansk, Pomorskie, 80-803, Poland|Twoja Przychodnia SCM, Szczecin, Zachodniopomorskie, 71-434, Poland|Local Institution - 0092, Lodz, ?ódzkie, 91-738, Poland|Local Institution, Moscow, 119991, Russian Federation|Local Institution, Moskva, 119571, Russian Federation|Local Institution - 0048, Badalona, Barcelona [Barcelona], 08916, Spain|Local Institution - 0051, Esplugues de Llobregat, Barcelona [Barcelona], 08950, Spain|Local Institution - 0044, Madrid, Madrid, Comunidad De, 28009, Spain|Hospital General Universitario Gregorio Mara?on, Madrid, 28007, Spain|Local Institution - 0050, Madrid, 28046, Spain|Local Institution - 0054, Birmingham, England, B4 6NH, United Kingdom|King's College Hospital, London, Greater London, SE5 9RS, United Kingdom|Local Institution - 0066, London, London, City Of, E1 1BB, United Kingdom Less << |
| NCT06529406 | Relapsing Multiple Sclerosis | PHASE4 | RECRUITING | 2029-08-01 | University of Colorado Anschut... More >>z Medical Campus, Aurora, Colorado, 80045, United States|Cleveland Clinic, Las Vegas, Nevada, 89106, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States Less << |
| NCT06334094 | Multiple Sclerosis | PHASE4 | WITHDRAWN | 2028-05-31 | Center for Brain Health, Dalla... More >>s, Texas, 75228, United States Less << |
| NCT05001152 | Healthy Volunteers | PHASE1 | COMPLETED | 2021-09-27 | Local Institution - 0001, Wobu... More >>rn, Massachusetts, 01801-6353, United States|Senopsys LLC, Woburn, Massachusetts, 01801, United States Less << |
| NCT04639115 | Liver Diseases|Digestive Syste... More >>m Diseases Less << | PHASE1 | COMPLETED | 2022-04-06 | University of Miami Miller Sch... More >>ool of Medicine, Miami, Florida, 33136, United States|Orlando Clinical Research Center OCRC, Orlando, Florida, 32809, United States|The Texas Liver Institute, San Antonio, Texas, 78215, United States Less << |
| NCT05809583 | Ulcerative Colitis | NOT_YET_RECRUITING | 2024-04-01 | Beth Israel Deaconess Medical ... More >>Center, Boston, Massachusetts, 02215, United States Less << | |
| NCT05319093 | Fatigue|Multiple Sclerosis | UNKNOWN | 2025-12-23 | - | |
| NCT06073873 | Ulcerative Colitis | RECRUITING | 2028-04-01 | Bristol-Myers Squibb YH, Seoul... More >>, 06178, Korea, Republic of Less << | |
| NCT05369832 | Colitis, Ulcerative | PHASE4 | ACTIVE_NOT_RECRUITING | 2025-04-15 | Local Institution - 0048, Doth... More >>an, Alabama, 36305-1156, United States|Local Institution - 0206, Chandler, Arizona, 85224-1636, United States|Local Institution - 0216, Gilbert, Arizona, 85297-0425, United States|Local Institution - 0125, Sun City, Arizona, 85351-2867, United States|Local Institution - 0195, Tucson, Arizona, 85724-0001, United States|Local Institution - 0045, North Little Rock, Arkansas, 72117-2927, United States|Local Institution - 0165, Apple Valley, California, 92307-1329, United States|Local Institution - 0162, Camarillo, California, 93012-5156, United States|Local Institution - 0014, Lancaster, California, 93534-5856, United States|OM Research LLC - Lancaster - ClinEdge - PPDS, Lancaster, California, 93534-5856, United States|Local Institution - 0209, Los Angeles, California, 90045-3119, United States|Local Institution - 0002, San Diego, California, 92103-5639, United States|Local Institution - 0208, San Diego, California, 92123-4207, United States|Local Institution - 0185, San Jose, California, 95116, United States|Local Institution - 0178, Littleton, Colorado, 80120-5641, United States|Gastro Florida, Clearwater, Florida, 33756-3839, United States|Local Institution - 0018, Clearwater, Florida, 33756-3839, United States|Local Institution - 0050, Homestead, Florida, 33033, United States|Local Institution - 0026, Lighthouse Point, Florida, 33064-7058, United States|Local Institution - 0049, Miami Lakes, Florida, 33016-5861, United States|Wellness Clinical Research-Miami Florida, Miami Lakes, Florida, 33016-5861, United States|Local Institution - 0167, Miami, Florida, 33136-1002, United States|Gastroenterology Group of Naples, Naples, Florida, 34102-5449, United States|Local Institution - 0003, Naples, Florida, 34102-5449, United States|Local Institution - 0058, Orange Park, Florida, 32073-4752, United States|Local Institution - 0205, Orlando, Florida, 32806-1110, United States|Local Institution - 0037, Palm Harbor, Florida, 34684, United States|Local Institution - 0179, Wellington, Florida, 33414-3187, United States|Local Institution - 0027, Roswell, Georgia, 30076-4969, United States|Local Institution - 0198, Arlington Heights, Illinois, 60005, United States|Local Institution - 0051, Chicago, Illinois, 60611, United States|Local Institution - 0098, Gurnee, Illinois, 60031, United States|Local Institution - 0192, Kansas City, Kansas, 66160-8500, United States|Local Institution - 0181, Topeka, Kansas, 66606-1539, United States|Local Institution - 0183, Louisville, Kentucky, 40202, United States|Local Institution - 0200, Baton Rouge, Louisiana, 70809-2440, United States|Local Institution - 0171, Chevy Chase, Maryland, 20815-7313, United States|Local Institution - 0191, Glen Burnie, Maryland, 21061-9121, United States|Local Institution - 0199, Boston, Massachusetts, 02111, United States|Local Institution - 0196, Worcester, Massachusetts, 01655, United States|Local Institution - 0174, Plymouth, Minnesota, 55446-3661, United States|Local Institution - 0184, Ocean Springs, Mississippi, 39564-5803, United States|Local Institution - 0024, Chesterfield, Missouri, 63005-1248, United States|Local Institution - 0213, Weldon Spring, Missouri, 63304-9103, United States|Local Institution - 0180, Englewood, New Jersey, 07631-4141, United States|Local Institution - 0084, Brooklyn, New York, 11203-2054, United States|Local Institution - 0187, New York, New York, 10016-6821, United States|Local Institution - 0059, New York, New York, 10016-9401, United States|NYU Langone Health -Inflammatory Bowel Disease Center, New York, New York, 10016-9401, United States|Local Institution - 0176, New York, New York, 10021, United States|Local Institution - 0170, Utica, New York, 13502, United States|Carolina Digestive Diseases, Greenville, North Carolina, 27834-3761, United States|Local Institution - 0005, Cincinnati, Ohio, 45229-3019, United States|University of Cincinnati Physicians Company, Cincinnati, Ohio, 45229-3019, United States|Local Institution - 0188, Columbus, Ohio, 43235-5424, United States|Local Institution - 0061, Mentor, Ohio, 44060-6521, United States|Local Institution - 0060, Providence, Rhode Island, 02905-3105, United States|Local Institution - 0177, Cordova, Tennessee, 38018-6362, United States|Local Institution - 0168, Nashville, Tennessee, 37211-4981, United States|Local Institution - 0038, Bellaire, Texas, 77401, United States|Novel Research LLC, Bellaire, Texas, 77401, United States|Local Institution - 0138, Dallas, Texas, 75246, United States|Local Institution - 0036, Houston, Texas, 77024-2469, United States|Local Institution - 0163, Houston, Texas, 77024-2469, United States|Ace Clinical Research Group: Digestive Health Associates, Houston, Texas, 77024, United States|Houston Methodist Hospital, Houston, Texas, 77030, United States|Local Institution - 0052, Houston, Texas, 77030, United States|Local Institution - 0129, Katy, Texas, 77494, United States|Local Institution - 0161, Lubbock, Texas, 79410-2014, United States|GI Alliance: Mansfield - TDDC, Mansfield, Texas, 76063-6083, United States|Local Institution - 0039, Mansfield, Texas, 76063-6083, United States|Local Institution - 0201, San Antonio, Texas, 78229-3270, United States|Local Institution - 0043, San Antonio, Texas, 78229-4463, United States|San Antonio Gastroenterology, San Antonio, Texas, 78229-4463, United States|Local Institution - 0166, San Marcos, Texas, 78666-7502, United States|Local Institution - 0046, Tyler, Texas, 75701-4464, United States|Tyler Research Institute, LLC, Tyler, Texas, 75701-4464, United States|Local Institution - 0091, Webster, Texas, 77598, United States|Local Institution - 0193, Ogden, Utah, 84403-3294, United States|Local Institution - 0169, Salt Lake City, Utah, 84132-0001, United States|Local Institution - 0197, Lynchburg, Virginia, 24502, United States|Local Institution - 0130, Seattle, Washington, 98104-1356, United States|Local Institution - 0189, Tacoma, Washington, 98405-2318, United States|Local Institution - 0017, Madison, Wisconsin, 53705-1311, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, 53792, United States Less << |
| NCT04140305 | Multiple Sclerosis | PHASE3 | ACTIVE_NOT_RECRUITING | 2026-04-27 | Local Institution - 123, Birmi... More >>ngham, Alabama, 35209, United States|Local Institution - 136, Cullman, Alabama, 35058, United States|Local Institution - 153, Mobile, Alabama, 36617, United States|Local Institution - 162, Phoenix, Arizona, 85018, United States|Local Institution - 128, Pasadena, California, 91105, United States|Local Institution - 164, Sacramento, California, 95817, United States|Local Institution - 107, Aurora, Colorado, 80045, United States|Local Institution - 102, Colorado Springs, Colorado, 80907, United States|Local Institution - 144, Fort Collins, Colorado, 80528, United States|Local Institution - 109, Washington, District of Columbia, 20007, United States|Local Institution - 140, Boca Raton, Florida, 33428, United States|Local Institution - 158, Vero Beach, Florida, 32960-4818, United States|Local Institution - 114, Savannah, Georgia, 31406, United States|Northwest Neurology, Ltd, Hoffman Estates, Illinois, 60169, United States|Local Institution - 108, Northbrook, Illinois, 60062, United States|Local Institution - 148, Fort Wayne, Indiana, 46825-1603, United States|Local Institution - 126, Ames, Iowa, 50010, United States|Local Institution - 173, Kansas City, Kansas, 66160, United States|Local Institution - 133, Alexandria, Louisiana, 71301, United States|Local Institution - 152, Detroit, Michigan, 48201, United States|Local Institution - 112, Detroit, Michigan, 48202, United States|Local Institution - 122, Saint Louis, Missouri, 63110, United States|Local Institution - 143, Saint Louis, Missouri, 63131, United States|Advanced Neurology Specialists, Great Falls, Montana, 59405, United States|Local Institution - 149, Teaneck, New Jersey, 07666, United States|Dent Neurologic Institute, Amherst, New York, 14226, United States|Local Institution - 137, Buffalo, New York, 14202, United States|Local Institution - 160, East Setauket, New York, 11733-3528, United States|Local Institution - 130, New York, New York, 10016, United States|Local Institution - 121, New York, New York, 10021, United States|Local Institution - 146, Patchogue, New York, 11772, United States|Local Institution - 131, Chapel Hill, North Carolina, 27514, United States|Local Institution - 106, Greensboro, North Carolina, 27405, United States|Local Institution - 170, Mooresville, North Carolina, 28117, United States|Raleigh Neurology Associates PA, Raleigh, North Carolina, 27607, United States|Local Institution - 174, Cincinnati, Ohio, 45219, United States|Local Institution - 171, Cleveland, Ohio, 44106, United States|UC Health, LLC, Dayton, Ohio, 45417, United States|Local Institution - 157, Oklahoma City, Oklahoma, 73104, United States|Local Institution - 159, Philadelphia, Pennsylvania, 19107, United States|Local Institution - 169, Philadelphia, Pennsylvania, 19140, United States|University of Pittsburgh Medical Center Magee Womens Hospital, Pittsburgh, Pennsylvania, 15213, United States|Local Institution - 125, Franklin, Tennessee, 37064, United States|Local Institution - 119, Knoxville, Tennessee, 37922, United States|Local Institution - 139, Dallas, Texas, 75246, United States|Local Institution - 113, Round Rock, Texas, 78681, United States|Local Institution - 101, San Antonio, Texas, 78259, United States|Local Institution - 103, Norfolk, Virginia, 23502, United States|Local Institution - 141, Kirkland, Washington, 98034, United States|Local Institution - 168, Seattle, Washington, 98101, United States|Local Institution - 172, Spokane, Washington, 99202, United States|Local Institution - 124, Tacoma, Washington, 98405, United States|Local Institution - 156, Huntington, West Virginia, 25701, United States|Local Institution - 150, Morgantown, West Virginia, 26506, United States|Local Institution - 167, Madison, Wisconsin, 53792, United States|Local Institution - 147, Milwaukee, Wisconsin, 53226, United States|Local Institution - 203, London, Ontario, N6G 2V4, Canada|Local Institution - 204, Ottawa, Ontario, K1H 8L6, Canada|Local Institution - 206, Montreal, Quebec, H2X 0A9, Canada|Local Institution - 207, Halifax, B3R 1V9, Canada|Local Institution - 166, Guaynabo, 00968, Puerto Rico Less << |
| NCT05470985 | Crohn Disease | PHASE2|PHASE3 | COMPLETED | 2024-09-13 | Local Institution - 0010, Gard... More >>en Grove, California, 92845-2032, United States|Local Institution - 0028, Los Angeles, California, 90027-6062, United States|Local Institution - 0002, Sacramento, California, 95817-2207, United States|Local Institution - 0009, San Francisco, California, 94158, United States|Local Institution - 0011, Hartford, Connecticut, 06106-3322, United States|Local Institution - 0044, Orlando, Florida, 32803-1469, United States|Local Institution - 0037, Orlando, Florida, 32806, United States|Local Institution - 0053, Atlanta, Georgia, 30302, United States|Local Institution - 0059, Indianapolis, Indiana, 46202-5109, United States|Local Institution - 0038, Springfield, Massachusetts, 01199, United States|Local Institution - 0006, Detroit, Michigan, 48201-2196, United States|Local Institution - 0003, Rochester, Minnesota, 55905-0001, United States|Local Institution - 0016, Saint Louis, Missouri, 63110-1002, United States|Local Institution - 0071, Lebanon, New Hampshire, 03756-1000, United States|Local Institution - 0060, New York, New York, 10032, United States|Local Institution - 0075, Fort Worth, Texas, 76104-2710, United States|Local Institution - 0070, Houston, Texas, 77030-2316, United States|Local Institution - 0008, Seattle, Washington, 98105-3901, United States|Local Institution - 0040, Tacoma, Washington, 98405-3720, United States|Local Institution - 0045, Joonladup, Western Australia, 6027, Australia|Local Institution - 0058, Brussel, BRU, 1020, Belgium|Local Institution - 0023, Leuven, VBR, 3000, Belgium|Local Institution - 0062, Liege, WLG, 4000, Belgium|Local Institution - 0048, Liège, WLG, 4000, Belgium|Local Institution - 0047, Brussel, 1090, Belgium|Local Institution - 0055, Bruxelles, 1200, Belgium|Local Institution - 0014, Halifax, Nova Scotia, B3K 6R8, Canada|Local Institution - 0001, London, Ontario, N6A 5W9, Canada|Local Institution - 0054, Montreal, Quebec, H3T 1C5, Canada|Local Institution - 0066, Bron, 69500, France|Local Institution - 0065, Caen, 14033, France|Local Institution - 0072, Paris, 75015, France|Local Institution - 0063, Toulouse, 31059, France|Local Institution - 0057, Dresden, SN, 01307, Germany|Local Institution - 0067, Leipzig, SN, 04103, Germany|Local Institution - 0015, Miskolc, 3526, Hungary|Local Institution - 0026, Szeged, 6720, Hungary|Local Institution - 0007, Warszawa, MZ, 00-728, Poland|Local Institution - 0052, Rzeszow, PK, 35-302, Poland|Local Institution - 0061, Lodz, 91-738, Poland|Local Institution - 0033, Warsaw, 04-746, Poland|Local Institution - 0031, Warszawa, 00-635, Poland|Local Institution - 0025, Barcelona, B, 8950, Spain|Local Institution - 0030, Badalona, 08916, Spain|Local Institution - 0035, Barcelone, 08035, Spain|Local Institution - 0017, Madrid, 28009, Spain Less << |
| NCT05382715 | Colitis, Ulcerative | RECRUITING | 2026-11-30 | Local Institution - 0001, Berl... More >>in, 10825, Germany Less << |
Tags: Ozanimod | RPC-1063 | RPC1063 | RPC 1063 | LPL Receptor | Lysophospholipid Receptor | sphingosine 1-phosphate | S1P receptor subtypes 1 (S1P1) | S1P receptor subtypes 5 (S1P5) | multiple sclerosis | neurosurgery | S1P receptor modulator | S1P1 modulator | S1P5 modulator | 1306760-87-1
Precautionary Statements-General | |
| Code | Phrase |
| P101 | If medical advice is needed,have product container or label at hand. |
| P102 | Keep out of reach of children. |
| P103 | Read label before use |
Prevention | |
| Code | Phrase |
| P201 | Obtain special instructions before use. |
| P202 | Do not handle until all safety precautions have been read and understood. |
| P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
| P211 | Do not spray on an open flame or other ignition source. |
| P220 | Keep/Store away from clothing/combustible materials. |
| P221 | Take any precaution to avoid mixing with combustibles |
| P222 | Do not allow contact with air. |
| P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
| P230 | Keep wetted |
| P231 | Handle under inert gas. |
| P232 | Protect from moisture. |
| P233 | Keep container tightly closed. |
| P234 | Keep only in original container. |
| P235 | Keep cool |
| P240 | Ground/bond container and receiving equipment. |
| P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
| P242 | Use only non-sparking tools. |
| P243 | Take precautionary measures against static discharge. |
| P244 | Keep reduction valves free from grease and oil. |
| P250 | Do not subject to grinding/shock/friction. |
| P251 | Pressurized container: Do not pierce or burn, even after use. |
| P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
| P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
| P262 | Do not get in eyes, on skin, or on clothing. |
| P263 | Avoid contact during pregnancy/while nursing. |
| P264 | Wash hands thoroughly after handling. |
| P265 | Wash skin thouroughly after handling. |
| P270 | Do not eat, drink or smoke when using this product. |
| P271 | Use only outdoors or in a well-ventilated area. |
| P272 | Contaminated work clothing should not be allowed out of the workplace. |
| P273 | Avoid release to the environment. |
| P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
| P281 | Use personal protective equipment as required. |
| P282 | Wear cold insulating gloves/face shield/eye protection. |
| P283 | Wear fire/flame resistant/retardant clothing. |
| P284 | Wear respiratory protection. |
| P285 | In case of inadequate ventilation wear respiratory protection. |
| P231 + P232 | Handle under inert gas. Protect from moisture. |
| P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
| Code | Phrase |
| P301 | IF SWALLOWED: |
| P304 | IF INHALED: |
| P305 | IF IN EYES: |
| P306 | IF ON CLOTHING: |
| P307 | IF exposed: |
| P308 | IF exposed or concerned: |
| P309 | IF exposed or if you feel unwell: |
| P310 | Immediately call a POISON CENTER or doctor/physician. |
| P311 | Call a POISON CENTER or doctor/physician. |
| P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
| P313 | Get medical advice/attention. |
| P314 | Get medical advice/attention if you feel unwell. |
| P315 | Get immediate medical advice/attention. |
| P320 | |
| P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
| P321 | |
| P322 | |
| P330 | Rinse mouth. |
| P331 | Do NOT induce vomiting. |
| P332 | IF SKIN irritation occurs: |
| P333 | If skin irritation or rash occurs: |
| P334 | Immerse in cool water/wrap n wet bandages. |
| P335 | Brush off loose particles from skin. |
| P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
| P337 | If eye irritation persists: |
| P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
| P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P342 | If experiencing respiratory symptoms: |
| P350 | Gently wash with plenty of soap and water. |
| P351 | Rinse cautiously with water for several minutes. |
| P352 | Wash with plenty of soap and water. |
| P353 | Rinse skin with water/shower. |
| P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
| P361 | Remove/Take off immediately all contaminated clothing. |
| P362 | Take off contaminated clothing and wash before reuse. |
| P363 | Wash contaminated clothing before reuse. |
| P370 | In case of fire: |
| P371 | In case of major fire and large quantities: |
| P372 | Explosion risk in case of fire. |
| P373 | DO NOT fight fire when fire reaches explosives. |
| P374 | Fight fire with normal precautions from a reasonable distance. |
| P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
| P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
| P378 | |
| P380 | Evacuate area. |
| P381 | Eliminate all ignition sources if safe to do so. |
| P390 | Absorb spillage to prevent material damage. |
| P391 | Collect spillage. Hazardous to the aquatic environment |
| P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
| P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
| P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
| P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
| P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
| P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
| P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
| P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
| P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
| P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
| P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
| P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
| P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
| P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
| P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
| P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
| P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
| P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
| P370 + P376 | In case of fire: Stop leak if safe to Do so. |
| P370 + P378 | In case of fire: |
| P370 + P380 | In case of fire: Evacuate area. |
| P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
| P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
| Code | Phrase |
| P401 | |
| P402 | Store in a dry place. |
| P403 | Store in a well-ventilated place. |
| P404 | Store in a closed container. |
| P405 | Store locked up. |
| P406 | Store in corrosive resistant/ container with a resistant inner liner. |
| P407 | Maintain air gap between stacks/pallets. |
| P410 | Protect from sunlight. |
| P411 | |
| P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
| P413 | |
| P420 | Store away from other materials. |
| P422 | |
| P402 + P404 | Store in a dry place. Store in a closed container. |
| P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
| P403 + P235 | Store in a well-ventilated place. Keep cool. |
| P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
| P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
| P411 + P235 | Keep cool. |
Disposal | |
| Code | Phrase |
| P501 | Dispose of contents/container to ... |
| P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
| Code | Phrase |
| H200 | Unstable explosive |
| H201 | Explosive; mass explosion hazard |
| H202 | Explosive; severe projection hazard |
| H203 | Explosive; fire, blast or projection hazard |
| H204 | Fire or projection hazard |
| H205 | May mass explode in fire |
| H220 | Extremely flammable gas |
| H221 | Flammable gas |
| H222 | Extremely flammable aerosol |
| H223 | Flammable aerosol |
| H224 | Extremely flammable liquid and vapour |
| H225 | Highly flammable liquid and vapour |
| H226 | Flammable liquid and vapour |
| H227 | Combustible liquid |
| H228 | Flammable solid |
| H229 | Pressurized container: may burst if heated |
| H230 | May react explosively even in the absence of air |
| H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
| H240 | Heating may cause an explosion |
| H241 | Heating may cause a fire or explosion |
| H242 | Heating may cause a fire |
| H250 | Catches fire spontaneously if exposed to air |
| H251 | Self-heating; may catch fire |
| H252 | Self-heating in large quantities; may catch fire |
| H260 | In contact with water releases flammable gases which may ignite spontaneously |
| H261 | In contact with water releases flammable gas |
| H270 | May cause or intensify fire; oxidizer |
| H271 | May cause fire or explosion; strong oxidizer |
| H272 | May intensify fire; oxidizer |
| H280 | Contains gas under pressure; may explode if heated |
| H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
| H290 | May be corrosive to metals |
Health hazards | |
| Code | Phrase |
| H300 | Fatal if swallowed |
| H301 | Toxic if swallowed |
| H302 | Harmful if swallowed |
| H303 | May be harmful if swallowed |
| H304 | May be fatal if swallowed and enters airways |
| H305 | May be harmful if swallowed and enters airways |
| H310 | Fatal in contact with skin |
| H311 | Toxic in contact with skin |
| H312 | Harmful in contact with skin |
| H313 | May be harmful in contact with skin |
| H314 | Causes severe skin burns and eye damage |
| H315 | Causes skin irritation |
| H316 | Causes mild skin irritation |
| H317 | May cause an allergic skin reaction |
| H318 | Causes serious eye damage |
| H319 | Causes serious eye irritation |
| H320 | Causes eye irritation |
| H330 | Fatal if inhaled |
| H331 | Toxic if inhaled |
| H332 | Harmful if inhaled |
| H333 | May be harmful if inhaled |
| H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
| H335 | May cause respiratory irritation |
| H336 | May cause drowsiness or dizziness |
| H340 | May cause genetic defects |
| H341 | Suspected of causing genetic defects |
| H350 | May cause cancer |
| H351 | Suspected of causing cancer |
| H360 | May damage fertility or the unborn child |
| H361 | Suspected of damaging fertility or the unborn child |
| H361d | Suspected of damaging the unborn child |
| H362 | May cause harm to breast-fed children |
| H370 | Causes damage to organs |
| H371 | May cause damage to organs |
| H372 | Causes damage to organs through prolonged or repeated exposure |
| H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
| Code | Phrase |
| H400 | Very toxic to aquatic life |
| H401 | Toxic to aquatic life |
| H402 | Harmful to aquatic life |
| H410 | Very toxic to aquatic life with long-lasting effects |
| H411 | Toxic to aquatic life with long-lasting effects |
| H412 | Harmful to aquatic life with long-lasting effects |
| H413 | May cause long-lasting harmful effects to aquatic life |
| H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL


